

Isolation and Identification of Lignans from *Caulis Bambusae* in *Taenia* with Antioxidant Properties

Jia Sun, Jin Yu, Pei-Cheng Zhang, Feng Tang, Yong-De Yue,* Ya-Nan Yang, Zi-Ming Feng, and Xue-Feng Guo

State Forestry Administration Key Open Laboratory, International Centre for Bamboo and Rattan, Beijing 100102, China

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, P. R. China

S Supporting Information

ABSTRACT: *Caulis Bambusae* in *Taenia* is a medicinal preparation from *Bambusa tuldoides* Munro consisting of skinless slices of the stem (bamboo shavings) and used as a traditional health food in tea, wine, and soup in Asia. Three novel lignans, (–)-7′-epi-lyoniresinol 4,9′-di-*O*-β-D-glucopyranoside (7), (–)-lyoniresinol 4,9′-di-*O*-β-D-glucopyranoside (8), bambulignan A (10), and seven known lignan compounds (1–6 and 9) were isolated from *Caulis Bambusae* in *Taenia*. The structures of the lignans were determined by detailed spectroscopic analysis (HRESIMS, HSQC, HMBC, NOE). All the isolated lignans were tested for antioxidant activities by DPPH and FARP assays. The results showed that the compounds (+)-lyoniresinol 9′-*O*-β-D-glucopyranoside (1) and (–)-7′-epi-lyoniresinol 9′-*O*-β-D-glucopyranoside (9) have strong free radical scavenging activity and reducing power.

KEYWORDS: *Bambusa tuldoides*, *Caulis Bambusae* in *Taenia*, (–)-7′-epi-lyoniresinol 4, 9′-di-*O*-β-D-glucopyranoside, (–)-lyoniresinol 4, 9′-di-*O*-β-D-glucopyranoside, bambulignan A, antioxidant activities, DPPH, FARP

INTRODUCTION

Bambusa tuldoides Munro is a widely distributed and cultivated bamboo species in southern China.¹ Sliced stem without the skin named “*Caulis Bambusae* in *Taenia*” or “Bamboo shavings” is used in traditional Chinese medicine and food. In Asia, *Caulis Bambusae* in *Taenia* has been used as a health food additive² and folk medicine for the treatments of tumors,³ fatigue,⁴ epilepsy,⁵ insomnia,⁶ and nausea and vomiting in pregnancy.⁷ In China, *Caulis Bambusae* in *Taenia* is a functional food certified by the Ministry of Health. More than 100 patents concerning addition of *Caulis Bambusae* in *Taenia* in foods, including tea,^{8,9} wine,^{10,11} and soup^{12,13} have been issued.

Studies on the chemical constituents and activity of *B. tuldoides* revealed the occurrence of molecules such as triterpenoids and polyphenols. However, less than five of these compounds have been isolated and identified.^{2,3,14} Although chemical and activity studies on crude extracts from *B. tuldoides* have been conducted, detailed chemical constituent analysis remains to be reported. As part of a research program studying the chemical diversity found in bamboo, with an emphasis on determining biological effects, the ethanol extract of *Caulis Bambusae* in *Taenia* has been investigated. Herein, we describe the isolation, structural elucidation, and biological assay of three novel lignans and seven known lignans from the *n*-butanol fraction of the extract.

Identification of the active compounds in *Caulis Bambusae* in *Taenia* and their biological effects are important in understanding how this medicinal product can be used to aid human health. The isolated lignans were tested by 1,1-diphenyl-2-picrylhydrazyl (DPPH) and ferric reducing/antioxidant power (FRAP) assays to evaluate their antioxidant activities.

MATERIALS AND METHODS

Plant Material. Dried *Caulis Bambusae* in *Taenia*, cultivated and processed in Guangzhou City (Guangdong Province, China), was purchased from Shucheng Market for Chinese Medicinal Material in Anhui, China. A voucher specimen was deposited in the State Forestry Administration Key Open Laboratory, International Centre for Bamboo and Rattan, Beijing 100102, China.

General Instrumental Equipment. Preparative HPLC was carried out on a Shimadzu LC-6AD instrument with an SPD-20A detector, using a YMC-Pack ODS-A column (250 × 20 mm, 5 μm). HPLC-DAD analysis was performed using a 1200 series system (Agilent Technologies, Waldbronn, Germany) with an Apollo C₁₈ column (250 × 4.6 mm, 5 μm, Grace Davison, Chicago, IL). Optical rotations were measured with a JASCO P-2000 polarimeter, and CD (Circular Dichroism) spectra were recorded on a JASCO J-815 CD spectrometer. IR spectra were taken on a Thermo Nicolet FT-IR NEXUS 670 spectrophotometer with KBr pellets. NMR spectra were run on INOVA 500 spectrometers. HRESIMS and ESI-MS spectra were obtained using an Agilent 6540 high resolution quadrupole time-of-flight (Q-TOF) mass spectrometer. DPPH and FARP assays were performed on PerkinElmer Lambda 35 UV–vis spectrometer.

Chemicals and Reagents. Column chromatography was performed with macroporous resin (Diaion HP-20, Mitsubishi Chemical Corp., Tokyo, Japan), Rp-18 (50 μm, YMC, Kyoto, Japan), Sephadex LH-20 (Pharmacia Fine Chemicals, Uppsala, Sweden). 1,1-Diphenyl-2-picrylhydrazyl (DPPH) was purchased from Aladdin Industry Corporation Shanghai. Trolox was purchased from Tokyo Chemical Industry Co., Ltd. 2,6-Di-*tert*-butyl-*p*-cresol (BHT), *tert*-butylhydroquinone (TBHQ), and pyrogallol acid were

Received: January 25, 2013

Revised: April 10, 2013

Accepted: April 11, 2013

Published: April 11, 2013

Table 1. NMR Spectroscopic Data (measured at 500 MHz) for Compounds 7, 8, and 10 (in DMSO) from the *n*-Butanol Fraction of an Extract from the Medicinal Preparation of *Caulis Bambusae* in *Taenia*

no.	compound 7		compound 8		compound 10	
	δ_C	δ_H , J in Hz	δ_C	δ_H , J in Hz	δ_C	δ_H , J in Hz
1	132.5		134.7		128.3	
2	126.8		125.8		104.8	6.24, 2H, s
3	151.4		151.8		147.9	
4	136.9		137.2		135.1	
5	150.7		151.3		147.9	
6	108.7	6.63, 1H, s	108.5	6.65, 1H, s	104.8	6.24, 2H, s
7	33.4	2.93, 2.68, 2H, dd, 12.0, 6.0	32.7	2.65, 2.56, 2H, dd, 11.5, 4.5	80.5	4.40, 1H, d, 4.0
8	33.5	1.76, 1H, m	39.7	1.55, 1H, m	39.6	3.04, 1H, m
9	63.2	3.40, 3.33, 2H, m	64.4	3.42, 3.37, 2H, m	68.9	4.26, 2H, m
1'	133.1		133.8		133.2	
2'	108.7		106.1		127.1	7.09, 7.07, 2H, d, 8.5
3'	147.6		148.0		115.1	6.65, 6.63, 2H, d, 8.5
4'	134.3		137.8		156.7	
5'	147.6		148.0		115.1	6.65, 6.63, 2H, d, 8.5
6'	108.7		106.1		127.1	7.09, 7.07, 2H, d, 8.5
7'	39.7	4.53, 1H, d, 4.5	40.8	4.24, 1H, d, 5.0	71.2	4.99, 1H, d, 3.0
8'	40.9	2.02, 1H, m	44.0	2.10, 1H, m	49.0	2.68, 1H, m
9'	69.0	3.62, 3.45, 2H, m	70.4	3.76, 3.48, 2H, m	178.1	
3-OCH ₃	60.2	3.28, 3H, s	60.7	3.44, 3H, s	56.3	3, 69, 6H, m
5-OCH ₃	56.5	3.79, 3H, s	56.6	3.78, 3H, s		
3',5'-OCH ₃	56.6	3.63, 6H, s	56.5	3.64, 6H, s		
		4-O-glucose				7-O-glucose
1''	103.4	4.87, 1H, d, 7.0	103.3	4.90, 1H, d, 7.0	101.5	4.10, 1H, d, 8.0
2''	74.8	3.11, 1H, m	74.7	3.13, 1H, m	74.8	3.01, 1H, m
3''	77.6	3.10, 1H, m	77.4	3.11, 1H, m	77.3	3.15, 1H, m
4''	70.4	3.12, 1H, m	70.4	3.14, 1H, m	70.5	3.13, 1H, m
5''	76.9	3.18, 1H, m	76.9	3.19, 1H, m	77.6	2.98, 1H, m
6''	61.3	3.61, 3.43, 2H, m	61.3	3.61, 3.42, 2H, m	61.0	3.57, 3.48, 2H, m
		9'-O-glucose				
1'''	103.5	4.19, 1H, d, 7.5	103.6	4.12, 1H, d, 7.5		
2'''	74.9	3.16, 1H, m	74.0	3.15, 1H, m		
3'''	77.8	3.12, 1H, m	77.3	3.13, 1H, m		
4'''	70.9	3.05, 1H, m	70.5	3.03, 1H, m		
5'''	77.3	3.02, 1H, m	77.0	3.01, 1H, m		
6'''	61.7	3.70, 3.48, 2H, m	61.6	3.70, 3.49, 2H, m		

purchased from Sinopharm Chemical Reagent Co., Ltd. 2,4,6-Tripyridyl-*s*-triazine was obtained from XiYa Reagent Company, ChengDu. Sodium acetate anhydrous was obtained from Beijing Chemical Works in China.

Analytical Techniques. The HPLC analysis was a binary elution system consisting of solvent A (methanol) and solvent B (water containing 0.2% acetic acid) with an Rp-18 column. The flow rate was 1 mL/min, and the column temperature was set at 30 °C. The injection volume was 10 μ L. The DAD detection wavelength was monitored at 220 nm. LC-MS analysis was carried out to confirm the molecular weight of compounds with an Rp-18 column at ESI-MS. The mobile phases were solvent A (methanol) and solvent C (water containing 0.1% formic acid). The flow rate was 0.2 mL/min. The column temperature was set at 30 °C, and the effluent was monitored at 220 nm. The mass spectrometer was equipped with a JetStream technology ESI ion source. The source parameters were as follows in negative ionization mode: Gas temperature: 350 °C, drying gas flow: 8 L/min, nebulizer: 35 psig, sheath gas temperature: 350 °C, sheath gas flow: 11 L/min, VCap: 3500 V, nozzle voltage (expt): 1000 V, fragmentor: 200 V, 250 V, 300 V, 350 V, 400 V, skimmer: 65 V, OCT 1 RF Vpp: 750 V, collision energy: 10 eV, 15 eV, 20 eV, 25 eV, 30 eV. The ¹H NMR spectra, ¹³C NMR spectra, and 2D NMR (HSQC, HMBC, and NOE) spectra were recorded on INOVA 500 spectrometers using DMSO-*d*₆ as solvent, and tetramethylsilane

(TMS) as an internal standard. Chemical shifts are expressed in δ (ppm), and coupling constants are reported in hertz. The concentration of compounds is 10 mg/mL, NMR acquisition duration is 2 min for ¹H NMR and 2 h for ¹³C NMR, and the width range of the NMR spectrum is 0–14 ppm for ¹H NMR and 0–220 ppm for ¹³C NMR.

Extraction, Isolation, and Purification of Compounds from *Caulis Bambusae* in *Taenia*. Dried *Caulis Bambusae* in *Taenia* (20 kg) was extracted three times with 95% aqueous ethanol at room temperature (1 day each in 20 L). The filtrates were combined and concentrated under reduced pressure for removal of the organic solvent. The concentrated aqueous fraction was extracted with ethyl acetate and *n*-butanol, which yielded an ethyl acetate fraction, *n*-butanol fraction, and water fraction. The *n*-butanol fraction (200 g) was separated on a macroporous resin column using a gradient of water–ethanol (100:0, 85:15, 70:30, 50:50, 5:95), giving five fractions. The 30% ethanol fraction (53.9 g) was applied to an Rp-18 column and eluted with gradient of water–methanol (100:0, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 50:50, 0:100), to give nine fractions (1–9). Fraction 6 (4 g) was further subjected to repeated column chromatography (CC) over Sephadex LH-20, eluting with water, and preparative HPLC eluting with methanol–water (15:85), to yield compounds 1 (840 mg), 2 (13 mg), 3 (21 mg), and 4 (12 mg). Fraction 5 (2.5 g) was separated by Sephadex LH-20 (water) CC, to




Figure 1. Compounds 1–10 isolated from *Caulis Bambusae* in *Taenia*.

give compounds 5 (25 mg), 7 (14 mg), and 8 (15 mg). Fraction 2 (1.5 g) was reappplied over Sephadex LH-20 (water) and preparative HPLC, eluting with methanol–water (10:90), which yielded compounds 6 (14 mg), 9 (13 mg), and 10 (10 mg).

(-)-7'-*epi*-Lyoniresinol 4,9'-*Di-O-β-D*-glucopyranoside (7). White amorphous powder; $[\alpha]_D -73.1^\circ$ (*c* 0.46, methanol). ESI-MS: *m/z* 743 $[M - H]^-$. HRESIMS ($C_{34}H_{48}O_{18}$) *m/z* 743.2761 $[M - H]^-$ (calculated for 743.2768). IR (KBr) cm^{-1} : ν_{max} 3433, 2924, 1630, 1401, 1111, 561. UV λ_{max} (methanol) ($\log \epsilon$): 274.8 nm. 1H and ^{13}C NMR (500 MHz) (DMSO-*d*₆), see Table 1.

(-)-Lyoniresinol 4,9'-*Di-O-β-D*-glucopyranoside (8). White amorphous powder; $[\alpha]_D -15.5^\circ$ (*c* 2.0, methanol). ESI-MS: *m/z* 743 $[M - H]^-$. HRESIMS ($C_{34}H_{48}O_{18}$) *m/z* 743.2779 $[M - H]^-$ (calculated for 743.2768). IR (KBr) cm^{-1} : ν_{max} 3423, 2928, 1611, 1458, 1413, 1223, 1110, 1075, 534. UV λ_{max} (methanol) ($\log \epsilon$): 274.8 nm. 1H and ^{13}C NMR (500 MHz) (DMSO-*d*₆), see Table 1.

Bambulignan A (10). White amorphous powder; $[\alpha]_D +3.78^\circ$ (*c* 0.6, methanol). ESI-MS: *m/z* 551 $[M - H]^-$. HRESIMS ($C_{26}H_{32}O_{13}$) *m/z* 551.1769 $[M - H]^-$ (calculated for 551.1770). IR (KBr) cm^{-1} : ν_{max} 3432, 2929, 1714, 1617, 1517, 1400, 1223, 1113, 1077, 536. UV λ_{max} (methanol) ($\log \epsilon$): 231.0, 274.8 nm. 1H and ^{13}C NMR (500 MHz) (DMSO-*d*₆), see Table 1.

Antioxidant Activity. The antioxidant activities of the isolated compounds 1–10 from *Caulis Bambusae* in *Taenia* were measured by two methods and compared.

DPPH Radical Scavenging Activity. The ability of samples to scavenge the DPPH radical (diphenylpicrylhydrazine) were monitored according to the method of Shimada¹⁵ with minor modifications. Briefly, a 0.3 mL aliquot of compound 1–10 (1.0 mg in 1.0 mL 95% ethanol) was added to 0.4 mL of the yellow-colored 1 mmol/L DPPH ethanol solution. The mixture was vortexed for 1 min and then left to stand at room temperature for 30 min in the dark. The absorbance was read at 517 nm with a Lambda 35 UV/visible spectrophotometer, which had been set to zero using a 95% ethanol solution. A decrease of the absorbance indicates an increase of DPPH radical scavenging activity. All samples were carried out in triplicate with BHT and TBHQ as positive controls. The ability to scavenge the DPPH radical was calculated using the following equation:¹⁶

$$\text{scavenging effect (\%)} \\ = [1 - (A_{\text{sample}} - A_{\text{sample blank}})/A_{\text{control}}] \times 100$$

where A_{control} is the absorbance of the control (DPPH solution without sample), A_{sample} is the absorbance of the test sample (DPPH solution plus test sample), and $A_{\text{sample blank}}$ is the absorbance of the sample only (sample without DPPH solution).

Ferric Reducing/Antioxidant Power (FRAP) Assay. The ferric reducing/antioxidant power of each sample was measured according to the method of Benzie and Strain¹⁷ with some modification. The stock solutions included 300 mM acetate buffer (5.1 g of CH_3COONa and 20 mL of CH_3COOH), 10 mM TPTZ (2,4,6-tripyridyl-*s*-triazine) solution in 40 mM HCl, and 20 mM $FeCl_3 \cdot 6H_2O$ solution. The fresh FRAP working solution was prepared by mixing 25 mL of acetate buffer, 2.5 mL of TPTZ solution, and 2.5 mL of $FeCl_3 \cdot 6H_2O$ solution and then warmed at 37 °C before using. A 0.05 mL aliquot of compound 1–10 (1.0 mg in 1.0 mL 95% ethanol) was added to 0.5 mL of FRAP working solution and 2.45 mL of distilled water. The mixture was shaken vigorously and then left to stand at 37 °C for 10 min in the water bath. The absorbance was read at 593 nm with a Lambda 35 UV/visible spectrophotometer, which had been set to zero using distilled water. High absorbance is an indication of high ferric reducing/antioxidant power. Each sample was run in triplicate. The standard control was 1.0 mmol/L $FeSO_4$, and trolox was used as a positive control.

RESULTS AND DISCUSSION

Isolation and Characterization. Repeated column chromatography over Sephadex LH-20, macroporous resin, Rp-18, and preparative HPLC of the 95% ethanol extract from *Caulis Bambusae* in *Taenia* led to isolation of three novel compounds, (-)-7'-*epi*-lyoniresinol 4,9'-*di-O-β-D*-glucopyranoside (7), (-)-lyoniresinol 4,9'-*di-O-β-D*-glucopyranoside (8), and bambulignan A (10), together with seven known compounds. The known ones were identified as (+)-lyoniresinol 9'-*O-β-D*-glucopyranoside (1),^{18–20} (-)-lyoniresinol 9'-*O-β-D*-glucopyranoside (2),²¹ (-)-5'-methoxyisolaricresinol 9'-*O-β-D*-glucopyranoside (3),²² (+)-lyoniresinol (4),²³ (+)-lyoniresinol 4-*O-β-D*-glucopyranoside (5),²⁴ (-)-lyoniresinol 9-*O-β-D*-glucopyranoside (6),²⁵ and (-)-7'-*epi*-lyoniresinol 9'-*O-β-D*-glucopyranoside (9)²⁵ (Figure 1), by comparison of their spectroscopic and physical data with those previously reported




Figure 2. Circular dichroism (CD) curves of the novel compounds **7** and **8** from *Caulis Bambusae* in *Taenia*.

in the literature. This was the first isolation of all 10 compounds from *Caulis Bambusae* in *Taenia*.

Compound **7** was obtained as a white powder, $[\alpha]_D -73.1^\circ$ ($c = 0.46$, MeOH, 20°C), and its molecular formula was determined as $\text{C}_{34}\text{H}_{48}\text{O}_{18}$ by negative HRESIMS (m/z 743.2761 $[\text{M} - \text{H}]^-$, calcd for 743.2768). All the spectra of compounds **7**, **8**, and **10** are shown in Supporting Information, and NMR assignments are gathered in Table 1. The IR spectrum showed absorption bands for hydroxyl group (3433 cm^{-1}), methylene (2924 cm^{-1}), and aromatic rings (1630 and 1401 cm^{-1}). The ^1H NMR and ^{13}C NMR spectra of compound **7** exhibited signals characteristic of an aryltetralin-type lignan glucoside.²⁶ In the HSQC spectrum, two anomeric proton signals at δ 4.87 (1H, d, $J = 7.0$) and δ 4.19 (1H, d, $J = 7.5$) correlated with corresponding carbon signals at δ 103.4 and δ 103.5 in the ^1H and ^{13}C NMR spectrum, which suggested compound **7** has two terminal β -D-glucopyranosyl units. In the HMBC analysis, the presence of a cross-peak between the anomeric proton δ 4.19 (H-1'') and δ 69.0 (C-9') revealed the location of the glucosidic linkage at the C-9' position. In the ^{13}C NMR spectrum (Table 1), the signals of **7** was similar to (+)-lyoniresinol 4,9'-di-O- β -D-glucopyranoside^{26,27} except for change of chemical shift at C-7,7',8,8'. Therefore, the relative configuration of compound **7** should be lyoniresinol 4,9'-di-O- β -D-glucopyranoside. The absolute configuration of compound **7** was determined by examination of the circular dichroism (CD) spectra (Figure 2). In the CD spectrum, the negative Cotton effects at 240 and 270 nm were observed (Figure 2).

Comparison to published CD spectra of (+)-lyoniresinol, (–)-lyoniresinol, and (–)-4-*epi*-lyoniresinol,²⁵ the absolute configuration of the aryl substituent at C-7' is *R* for compound **7**. Furthermore, compared with ^{13}C NMR spectra of (–)-lyoniresinol and (–)-4-*epi*-lyoniresinol,²⁵ the signals of compound **7** at C-7/8 and 7'/8' were the same as (–)-4-*epi*-lyoniresinol C-7/8 and 7'/8'. The result showed that the structure of compound **7** was (–)-4-*epi*-lyoniresinol 4,9'-di-O- β -D-glucopyranoside.

Compound **8** was also obtained as a white powder, $[\alpha]_D -15.5^\circ$ ($c = 2.0$, MeOH, 20°C), and its molecular formula was determined to be $\text{C}_{34}\text{H}_{48}\text{O}_{18}$ by negative HRESIMS (m/z 743.2779 $[\text{M} - \text{H}]^-$, calcd for 743.2768). The IR and UV spectra of **7** and **8** showed similar absorption patterns. In the ^1H and ^{13}C NMR spectra (Table 1), the signals of compound **8** were similar to those of compound **7** except for a field shift at C-7,7',8,8'. For compound **8**, the observed C-8 was +6.2 ppm and C-8' was +3.1 ppm in the ^{13}C NMR spectrum (Table 1). Furthermore, the CD spectrum showed negative Cotton effects at 240 and 270 nm in **8** (Figure 2), which indicated the absolute configuration of the aryl substituent at C-7' is *R*. Comparison of the ^{13}C NMR spectra of (–)-lyoniresinol and compound **8** showed that C-7/8 and 7'/8' were similar. Therefore, the absolute configuration of **8** was concluded to be that of (–)-lyoniresinol. The structure was determined to be (–)-lyoniresinol 4,9'-di-O- β -D-glucopyranoside.

Compound **10** was obtained as a white amorphous powder, and HRESIMS afforded a quasimolecular ion $[\text{M} - \text{H}]^-$ at m/z

551.1769 (calculated for 551.1770). The ESIMS suggested the molecular formula to be $C_{26}H_{32}O_{13}$. The IR spectrum showed absorption bands for hydroxyl group (3432 cm^{-1}), aromatic rings (1617 and 1400 cm^{-1}), and carbonyl group (1614 cm^{-1}). The ^1H NMR spectrum revealed the presence of six aromatic protons at δ 7.09 (2H), δ 6.65 (2H), δ 6.24 (2H) and two aryl-substituted methoxyl groups at δ 3.69, showing a typical pattern for a 3,5-dimethoxy-4-hydroxyphenyl group and a 4-hydroxyphenyl group. Furthermore, the anomeric proton at δ 4.10 (d, $J = 8.0$) indicated a β -glycoside linkage for the D-glucose moiety, and there were two aromatic moieties and a β -D-glucopyranosyl unit in the lignan.^{28,29} In the ^{13}C NMR spectrum, besides the 3,5-dimethoxy-4-hydroxyphenyl and 4-hydroxyphenyl groups, six carbon signals at δ 178.1 (carbonyl), δ 80.5, δ 71.2, δ 68.9 (oxygenated carbons), and δ 49.0, δ 39.6 (methine carbons), and a β -D-glucopyranosyl unit at δ 101.5, δ 74.8, δ 77.3, δ 70.5, δ 77.6, δ 61.0 were also observed. In the HMBC spectrum, the anomeric protons δ 4.10 (H-1''), δ 6.24 (H-2,6), δ 2.68 (H-8'), and δ 4.26 (H-9) were correlated to δ 80.5 (C-7), implying that the O-glycoside was linked to δ 80.5 (C-7). Both δ 4.99 (H-7') and δ 2.68 (H-8') were correlated to δ 178.1 (C-9'), δ 4.99 (H-7') was also correlated to δ 133.2 ppm (C-1') and δ 127.1 ppm (C-2',6'), which confirmed that the furanone was linked to the 4-hydroxyphenyl group (Figure 3). The NOESY experiment on compound **10** showed




Figure 3. Key HMBC correlations of compound **10**.

correlations between δ 2.68 (H-8', m) and δ 4.40 (H-7, d), δ 4.99 (H-7', d) and between δ 4.40 (H-7, d) and δ 3.04 (H-8, m), and we presume that C-8 and C-8' may be R' and R' . The CD spectrum showed negative Cotton effects at 257 and 287 nm. Comparison with podorhizol and analogous compounds^{30,31} suggested that the configurations of C-8 and C-8' are 8S and 8'R. Regarding the configuration of C-7', it has been reported that a proton of 5'-methoxypodorhizol appeared at δ 5.28 ($J = 3.0$ Hz) in 5'-methoxypodorhizol.³² In compound **10**, a C-7' proton appears at δ 4.99 ($J = 3.0$ Hz), revealing that the configuration of C-7' is S. Therefore, the structure of compound **10** was assigned a O-glucopyranosyl unit connected to the C-7 position, and a 4-hydroxyphenyl group is included in the partial structures of **10**, so the compound has been named bambulignan A (Figure 1).

Free Radical Scavenging Activities of Isolated Compounds. DPPH Radical Scavenging Assay. DPPH is a useful reagent for investigating the free radical-scavenging activities of compounds.³³ The DPPH (diphenylpicrylhydrazine) method is based on the reduction of DPPH solution in the presence of a hydrogen-donating antioxidant to the nonradical form DPPH-H.³⁴ The isolated compounds **1–10** and the controls TBHQ, BHT, and trolox were assayed for antioxidant effects in the DPPH free radical scavenging assay and FRAP assay.^{35,36}

The DPPH free radical scavenging ability of each sample is shown in Figure 4. All compounds exhibited DPPH radical scavenging activity. The scavenging actions of compounds **1** and **9** were higher than that of the controls (TBHQ, BHT). All compounds except compound **7** showed potent DPPH radical scavenging activity.

Ferric Reducing/Antioxidant Power (FRAP) Assay. Studies have indicated that antioxidant effects are related to the development of reductones.^{33,34,37} Reductones were reported to be terminators of free radical chain reactions and can be measured by the FRAP (ferric reducing/antioxidant power) method. These reductants may limit free radical damage in biological systems.^{35,36} Thus, the reductive (H acceptor) activities of the antioxidant compounds from *Caulis Bambusae* in *Taenia* were assayed using the FRAP method. The abilities of the isolated compounds **1–10** and trolox for reducing the FeCl_3 are seen in Figure 5. All 10 compounds possessed the ability to reduce iron(III). Compound **4** showed the strongest reducing power. Compounds **1** and **9** also had notable reducing




Figure 4. DPPH free radical scavenging ability of the isolated lignan compounds from *Caulis Bambusae* in *Taenia* and the positive controls BHT and TBHQ.




Figure 5. Ferric reducing/antioxidant power of isolated lignan compounds from *Caulis Bambusae* in *Taenia* and the positive control trolox.

power. Interestingly, all compounds reported reducing power higher than that of the control (trolox).

According to the results of the DPPH free radical scavenging and FRAP reducing power assays, the antioxidant activities of compounds **1** and **9** were better than that of the other compounds. Because free hydroxyl groups in phenolic compounds are mainly responsible for antioxidant activity,³⁸ it is worth noting that compounds **1** and **9** both contain multiple phenolic hydroxyl groups, and their configuration also has a certain effect for the antioxidant activity.

■ ASSOCIATED CONTENT

● Supporting Information

¹H, ¹³C, HSQC, and HMBC spectra of (–)-7'-*epi*-lyoniresinol 4,9'-di-*O*-β-D-glucopyranoside (**7**), ¹H, ¹³C, and HMBC spectra of (–)-lyoniresinol 4,9'-di-*O*-β-D-glucopyranoside (**8**), ¹H, ¹³C, HSQC, HMBC, and NOESY spectra of bambulignan A (**10**) in DMSO. IR, HRESIMS, and CD spectra of (–)-7'-*epi*-lyoniresinol 4,9'-di-*O*-β-D-glucopyranoside (**7**), (–)-lyoniresinol 4,9'-di-*O*-β-D-glucopyranoside (**8**), and bambulignan A (**10**). This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: + 86 10 8478 9868. Fax: + 86 10 8478 9821. E-mail: yueyd@icbr.ac.cn.

Funding

This work was supported by National Science and Technology Infrastructure Program (No. 2012BAD23B03) and Basic Science Research Fund Program of the International Centre for Bamboo and Rattan (ICBR) (13618–6).

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We are grateful to the staff of the analytical group at Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences & Peking Union Medical College, and State Forestry Administration Key Open Laboratory, International Centre for Bamboo and Rattan, for measuring the spectroscopic data.

■ REFERENCES

- Jiang, Z. H. Conservation of bamboo resources and genetic improvement. *Bamboo and Rattan in the World*; China Forestry Publishing House: Beijing, China, 2007; pp 54–55.
- Zhao, A. H. A health tea for preventing and treating coronary atherosclerotic heart disease. CN Patent CN101617812, Jan 2010.

- Lu, B. Y.; Liu, L. L.; Zhen, X. W.; Wu, X. Q.; Zhang, Y. Antitumor activity of triterpenoid-rich extract from bamboo shavings (*Caulis bambusae in Taeniam*). *Afr. J. Biotechnol.* **2010**, *38*, 6430–6436.

- Zhang, Y.; Yao, X. B.; Bao, B. L.; Zhang, Y. Anti-fatigue activity of a triterpenoid-rich extract from Chinese bamboo shavings (*Caulis bambusae in Taeniam*). *Phytother. Res.* **2006**, *10*, 872–876.

- Sun, Y. F. Method for preparing Chinese medicine oral wine for treating epilepsy. CN Patent CN101601820, Dec 2009.

- Yin, K. S. A Chinese medicine containing Folium Perillae, and *Caulis Bambusae in Taenia* for treating the sickness of stomach in early gestation. CN Patent CN101152477, Apr 2008.

- Teng, S. L. A traditional Chinese medicine for the treatment of nausea and vomiting of pregnancy. CN Patent CN101537166, Sep 2009.

- Meng, X. M. A health tea to eliminate sputum for elderly people. CN Patent CN101569403, Nov 2009.

- Lin, Z. Y.; Wu, T. Z. Tea for cleaning gallbladder and removing calculus. CN Patent CN101011540, Aug 2007.

- Jung, J. N. Method for manufacturing traditional wine with *Bambusae caulis in taenia*. KR Patent 2012133194, Dec 2012.

- Li, J. Preparation methods for a series of tonic health brandy wines. CN Patent CN1160080, Sep 1997.

- Wang, K. A pharmaceutical composition for the treatment of leukemia. CN Patent CN1390588, Aug 2003.

- He, Z. H. Instant soup of fungus and black-bone chicken. CN Patent CN1303627, Jun 2001.

- Gong, J. Y.; Wu, X. Q.; Lu, B. Y.; Zhang, Y. Safety evaluation of polyphenol-rich extract from bamboo shavings. *Afr. J. Biotechnol.* **2010**, *9*, 77–86.

- Shimada, K.; Fujikawa, K.; Yahara, K. Antioxidative properties of xanthan on the autoxidation of soybean oil in cyclodextrin emulsion. *J. Agric. Food Chem.* **1992**, *40*, 945–948.

- Shyu, Y. S.; Hwang, L. S. Antioxidative activity of the crude extract of lignan glycosides from unroasted Burma black sesame meal. *Food Res. Int.* **2002**, *35*, 357–365.

- Benzie, I. F.; Strain, J. J. The ferric reducing ability of plasma as a measure of “antioxidant power”: the FRAP assay. *Anal. Biochem.* **1996**, *239*, 70–76.

- Yoshimoto, K.; Itatani, Y.; Tsuda, Y. ¹³C-nuclear magnetic resonance (NMR) spectra of O-acylglucosides-additivity of shift parameters and its application to structure elucidations. *Chem. Pharm. Bull.* **1980**, *28*, 2065–2076.

- Tanaka, O. Application of ¹³C-nuclear magnetic resonance spectrometry to structural studies on glycosides: saponins of *Panax* spp. and natural sweet glycosides. *Yakugaku Zasshi* **1985**, *105*, 323–351.

- Shibuya, H.; Takeda, Y.; Zhang, R. S.; Tanitame, A.; Tsai, Y. L.; Kitagawa, I. Indonesian Medicinal Plants. IV. On the constituents of the Bark of *Fagara rhetza* (Rutaceae). Lignan glycosides and two apioglucosides. *Chem. Pharm. Bull.* **1992**, *40*, 2639–2646.

- Dad, G.; Corbani, A.; Manitto, P.; Speranza, G.; Lunazzi, L. Lignan glycosides from the heartwood of European oak *Quercus petraea*. *J. Nat. Prod.* **1989**, *52*, 1327–1330.

- (22) Achenbach, H.; Löewel, M.; Waibel, R.; Gupta, M.; Solis, P. New lignan glucosides from *Stemmadenia minima*. *Planta Med.* **1992**, *58*, 270–272.
- (23) Tanaka, T.; Ito, T.; Ido, Y.; Nakaya, K.; Iinuma, M. Hopeafuran and a C-glucosyl resveratrol isolated from stem wood of *Hopea utilis*. *Chem. Pharm. Bull.* **2001**, *49*, 785–787.
- (24) Su, D. M.; Wang, Y. H.; Yu, S. S.; Yu, D. Q.; Hu, Y. C.; Tang, W. Z.; Liu, G. T.; Wang, W. J. Glucosides from the roots of *Capparis tenera*. *Chem Biodivers.* **2007**, *4*, 2852–2862.
- (25) Kazuyoshi, O.; Hisashi, W.; Yasuaki, O. Indonesian Medicinal Plants. XII: Four Isomeric Lignan-glucosides from the bark of *Aegle marmelos* (*Rutaceae*). *Chem. Pharm. Bull.* **1994**, *42*, 1924–1926.
- (26) Achenbach, H.; Benirschke, M.; Torrenegra, R. Alkaloids and other compounds from seeds of *Tabernaemontana cymosa*. *Phytochemistry* **1997**, *45*, 325–335.
- (27) Li, X. C.; Barnes, D. L.; Khan, I. A. A New Lignan Glycoside from *Eleutherococcus senticosus*. *Planta Med.* **2001**, *67*, 776–778.
- (28) Buske, A.; Schmidt, J.; Porzel, A.; Adam, G. Alkaloidal, megastigmane and lignan Glucosides from *Antidesma membranaceum* (*Euphorbiaceae*). *Eur. J. Org. Chem.* **2001**, *2001*, 3537–3543.
- (29) Higuchi, H.; Fukui, K.; Kinjo, J.; Nohara, T. Four New Glycosides from *Albizia Cortex*. III. *Chem. Pharm. Bull.* **1992**, *40*, 534–535.
- (30) Ogawa, M.; Ogiwara, Y. Studies on the constituents of *Enkianthus nudipes*. V. A New Lignan Xyloside from the Stems. *Chem. Pharm. Bull.* **1976**, *24*, 2102–2015.
- (31) Tanguchi, M.; Hosono, E.; Kitaoka, M.; Arimoto, M.; Yamaguchi, H. Studies on constituents of the seeds of *Hernandia ovigera*. IX. Identification of Two Dibenzylbutyrolactone-Type Lignans and an Attempt of Conversion into Phenyltetralin-Type Lignan. *Chem. Pharm. Bull.* **1991**, *39*, 1873–1876.
- (32) Nishibe, S.; Hisada, S.; Inagaki, I. The ether-soluble lignans of *Trachelospermum asiaticum* var. *intermedium*. *Phytochemistry* **1971**, *10*, 2231–2232.
- (33) Duan, X. J.; Zhang, W. W.; Li, X. M.; Wang, B. G. Evaluation of antioxidant property of extract and fractions obtained from a red alga. *Polysiphonia urceolata*. *Food Chem.* **2006**, *95*, 37–43.
- (34) Shon, M. Y.; Kim, T. H.; Sung, N. J. Antioxidants and free radical scavenging activity of *Phellinus baumii* (*Phellinus of Hymenochaetaceae*) extracts. *Food Chem.* **2003**, *82*, 593–597.
- (35) Brand-Williams, W.; Cuvelier, M. E.; Berset, C. Use of a free radical method to evaluate antioxidant activity. *LWT-Food Sci. Technol.* **1995**, *28*, 25–30.
- (36) Pan, Y. M.; Wang, K.; Huang, S. Q.; Wang, H. S.; Mu, X. M.; He, C. H.; Ji, X. W.; Zhang, J.; Huang, F. J. Antioxidant activity of microwave-assisted extract of longan (*Dimocarpus Longan* Lour.) peel. *Food Chem.* **2008**, *106*, 1264–1270.
- (37) Dorman, H. J. D.; Kosar, M.; Kahlos, K.; Holm, Y.; Hiltunen, R. Antioxidant properties and composition of aqueous extracts from *Mentha* species, hybrids, varieties, and cultivars. *J. Agric. Food Chem.* **2003**, *51*, 4563–4569.
- (38) Liu, F.; Ng, T. B. Antioxidative and free radical scavenging activities of selected medicinal herbs. *Life Sci.* **2000**, *66*, 725–735.